Combination therapy with conditionally replicating adenovirus and replication defective adenovirus.
Low gene transfer rate is the most substantial hurdle in the practical application of gene therapy. One strategy to improve transfer efficiency is the use of a conditionally replicating adenovirus (CRAD) that can selectively replicate in tumor cells. We hypothesized that conventional E1-deleted adenoviruses (ad) can become replication-competent when cotransduced with a CRAD to selectively supply E1 in trans in tumors. The resulting selective production of large numbers of the E1-deleted ad within the tumor mass will increase the transduction efficiency. We used a CRAD (Delta24RGD) that produces a mutant E1 without the ability to bind retinoblastoma but retaining viral replication competence in cancer cells with a defective pRb/p16. Ad-lacZ, adenovirus-luciferase (ad-luc), and adenovirus insulin-like growth factor-1R/dominant-negative (ad-IGF-1R/dn; 482, 950) are E1-deleted replication-defective adenoviruses. The combination of CRAD and ad-lacZ increased the transduction efficiency of lacZ to 100% from 15% observed with ad-lacZ alone. Transfer of media of CRAD and ad-lacZ cotransduced cells induced the transfer of lacZ (media transferable bystander effect). Combination of CRAD and ad-IGF-1R/dn increased the production of truncated IGF-1R or soluble IGF-1R > 10 times compared with transduction with ad-IGF-1R/dn alone. Combined intratumoral injection of CRAD and ad-luc increased the luciferase expression about 70 times compared with ad-luc alone without substantial systemic spread. Combined intratumoral injection of CRAD and ad-IGF-1R/482 induced stronger growth suppression of established lung cancer xenografts than single injections. The combination of CRAD and E1-deleted ad induced tumor-specific replication of CRAD and E1-deleted ad and increased the transduction rate and therapeutic efficacy of these viruses in model tumors.
Lee
Choon-Taek
CT
Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37322-6838, USA.
Park
Kyung-Ho
KH
Yanagisawa
Kiyoshi
K
Adachi
Yasushi
Y
Ohm
Joyce E
JE
Nadaf
Sorena
S
Dikov
Mikhail M
MM
Curiel
David T
DT
Carbone
David P
DP
D000256:Adenoviridae / Q000235:genetics / Q000502:physiology*; D017498:Adenovirus E1 Proteins / Q000172:deficiency / Q000235:genetics; D045744:Cell Line, Tumor; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007763:Lac Operon / Q000235:genetics; D008156:Luciferases / Q000096:biosynthesis / Q000235:genetics; D008175:Lung Neoplasms / Q000235:genetics / Q000628:therapy / Q000821:virology; D017526:Receptor, IGF Type 1 / Q000235:genetics; D014161:Transduction, Genetic / Q000379:methods; D019076:Transgenes; D014779:Virus Replication / Q000502:physiology*; D023041:Xenograft Model Antitumor Assays
D017498:Adenovirus E1 Proteins; D008156:Luciferases; D017526:Receptor, IGF Type 1